StockNews.AI
TECH
StockNews.AI
162 days

Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System

1. Bio-Techne launches Leo™ System for automated protein quantitation. 2. Leo significantly improves sample throughput and processing speed. 3. The system enhances data quality for regulatory submissions. 4. Early users report excellent performance across various research applications. 5. Leo accelerates scientific development and market readiness for therapies.

5m saved
Insight
Article

FAQ

Why Bullish?

The launch of the Leo™ System enhances Bio-Techne's competitive edge in biotech. Historically, strong product launches have led to significant stock price increases for similar companies in the sector.

How important is it?

The introduction of innovative technology like the Leo™ System can significantly influence revenue and investor sentiment. Positive user feedback further elevates its significance.

Why Short Term?

Immediate revenue benefits from sales of Leo can impact results in upcoming quarters. Quick adoption by labs and researchers will drive early financial gains.

Related Companies

NDAQ: TECHNDAQ: VRTXNDAQ: REGN
, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization. Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run, offering 4x the throughput of the Jess™ Simple Western System and 5x faster turn-around-times than Sally Sue™ and Peggy Sue™ Simple Western Systems. Leo also provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies. Additionally, Leo features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance.  "With Leo, scientists can achieve their development milestones faster and more efficiently, completing studies with fewer runs, operators and instruments," commented Will Geist, President of Bio-Techne's Protein Sciences Segment. "Leo will enable our customers to accelerate their cutting-edge science and bring next generation therapies to market faster." Early adopters have been thrilled with the power that Leo brings, with beta testers praising the instrument's robust performance, data quality, and wide range of applications, including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control and release assays, recombinant protein expression and more. Explore Leo's capabilities at bio-techne.com/leo. Data on Leo's performance will be presented at an upcoming webinar. Registration details can be found here. About Bio-Techne Corporation (NASDAQ: TECH)Contact: David Clair, Vice President, Investor Relations & Corporate Development[email protected] 612-656-4416 SOURCE Bio-Techne Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News